MA34042B1 - Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf - Google Patents

Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf

Info

Publication number
MA34042B1
MA34042B1 MA34424A MA34424A MA34042B1 MA 34042 B1 MA34042 B1 MA 34042B1 MA 34424 A MA34424 A MA 34424A MA 34424 A MA34424 A MA 34424A MA 34042 B1 MA34042 B1 MA 34042B1
Authority
MA
Morocco
Prior art keywords
compounds
formulas
cancer
pyridines
pyrrolo
Prior art date
Application number
MA34424A
Other languages
Arabic (ar)
English (en)
Inventor
Prabha N Ibrahim
Wayne Spevak
Hanna Cho
Songyuan Shi
Guoxian Wu
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34042(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of MA34042B1 publication Critical patent/MA34042B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des composés (i) et des sels de ceux-ci, sur des formulations de ceux-ci, sur des conjugués de ceux-ci, sur des dérivés de ceux-ci, sur des formes de ceux-ci et sur leurs utilisations. Sous certains aspects et modes de réalisation, les composés décrits ou sels de ceux-ci, formulations de ceux-ci, conjugués de ceux-ci, dérivés de ceux-ci et formes de ceux-ci sont actifs sur chacune des protéines kinases braf et c-raf-1, et peuvent également être actifs sur l'une ou l'autre protéine kinase a-raf ou b-raf v600e ou sur les deux. L'invention porte également sur des procédés d'utilisation des composés pour traiter des maladies et des états pathologiques, tels qu'un mélanome, un cancer colorectal, un cancer de la thyroïde, un cancer de l'ovaire et un cancer du tractus biliaire.
MA34424A 2009-05-06 2010-05-04 Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf MA34042B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17605409P 2009-05-06 2009-05-06
PCT/US2010/033571 WO2010129567A1 (fr) 2009-05-06 2010-05-04 Pyrrolo [2, 3. b] pyridines qui inhibent la protéine kinase raf

Publications (1)

Publication Number Publication Date
MA34042B1 true MA34042B1 (fr) 2013-03-05

Family

ID=42236712

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34424A MA34042B1 (fr) 2009-05-06 2010-05-04 Pyrrolo [2, 3. b ]pyridines qui inhibent la protéeine kinase raf

Country Status (23)

Country Link
US (3) US20120122860A1 (fr)
EP (2) EP2427433A1 (fr)
JP (2) JP2012526128A (fr)
KR (1) KR20140014386A (fr)
CN (1) CN102459262A (fr)
AR (1) AR076749A1 (fr)
AU (1) AU2010246005A1 (fr)
BR (1) BRPI1013843A2 (fr)
CA (1) CA2759997A1 (fr)
CL (1) CL2011002739A1 (fr)
CR (1) CR20110562A (fr)
EC (1) ECSP11011437A (fr)
IL (1) IL215908A0 (fr)
MA (1) MA34042B1 (fr)
MX (1) MX2011011737A (fr)
NI (1) NI201100189A (fr)
NO (1) NO20111508A1 (fr)
PE (1) PE20120518A1 (fr)
RU (1) RU2011149485A (fr)
SG (1) SG175810A1 (fr)
TW (1) TW201041888A (fr)
WO (2) WO2010129567A1 (fr)
ZA (1) ZA201108124B (fr)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2738573C (fr) 2009-04-03 2013-02-19 F. Hoffmann-La Roche Ag Compositions et utilisations associees
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
EP2501236B1 (fr) 2009-11-18 2017-03-29 Plexxikon Inc. Dérivés de la benzènesulfonamide de N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phényl]-4- en tant que modulateurs de la kinase du protein Raf pour le traitement du cancer
CA2784393A1 (fr) 2009-12-23 2011-06-30 Plexxikon, Inc. Composes et methodes pour la modulation des kinases, et leurs indications
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) * 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
JP6112512B2 (ja) * 2010-12-01 2017-04-12 レクシ ファーマ インコーポレイテッド 難治性癌を治療するための方法
US8889684B2 (en) * 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
PE20141360A1 (es) * 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.
TWI558702B (zh) * 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
WO2012138809A1 (fr) * 2011-04-05 2012-10-11 Dawei Zhang Utilisation de composés hétérocycliques en tant qu'inhibiteurs des kinases
EP2670866A4 (fr) * 2011-04-05 2015-09-02 Translational Genomics Res Inst Biomarqueurs et leurs procédés d'utilisation
CA2836474A1 (fr) 2011-05-17 2012-11-22 Plexxikon Inc. Modulation de kinase et indications pour celle-ci
WO2013032951A1 (fr) 2011-08-26 2013-03-07 Neupharma, Inc. Entités chimiques, compositions et procédés
CN102993199A (zh) * 2011-09-09 2013-03-27 山东轩竹医药科技有限公司 杂环取代的吡啶并吡咯激酶抑制剂
AU2012308238B2 (en) 2011-09-14 2017-05-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
WO2013049701A1 (fr) 2011-09-30 2013-04-04 Neupharma, Inc. Certaines entités chimiques, compositions et procédés
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
EP2806874B1 (fr) 2012-01-25 2017-11-15 Neupharma, Inc. Dérivés de quinoxaline-oxy-phenyl comme inhibiteurs de kinases
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
JP6013029B2 (ja) * 2012-05-25 2016-10-25 千葉県 抗癌剤
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US9150570B2 (en) * 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
WO2014008270A1 (fr) 2012-07-03 2014-01-09 Ratiopharm Gmbh Forme solide du sel de choline de vemurafénib
DE102012016908A1 (de) * 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
TWI601725B (zh) 2012-08-27 2017-10-11 加拓科學公司 取代的氮雜吲哚化合物及其鹽、組合物和用途
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
CN103613591B (zh) * 2012-09-29 2016-04-13 上海科州药物研发有限公司 作为cMet抑制剂的化合物及其制备方法和用途
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
JP2016500076A (ja) 2012-11-20 2016-01-07 プリンシピア バイオファーマ インコーポレイテッド Ｊａｋ３阻害剤としてのアザインドール誘導体
ME03000B (fr) 2012-12-21 2018-10-20 Plexxikon Inc Composés et procédés pour la modulation de kinase, et indications associées
MX2015009270A (es) 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
EP2970270A1 (fr) * 2013-03-14 2016-01-20 ratiopharm GmbH Formes solides de chlorhydrate de vémurafénib
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN105073747B (zh) 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
WO2015075749A1 (fr) * 2013-11-22 2015-05-28 Laurus Labs Private Limited Nouveaux procédés de préparation de vemurafenib
CZ2013943A3 (cs) 2013-11-27 2015-06-03 Zentiva, K.S. Krystalické formy vemurafenibu
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
NO2714752T3 (fr) * 2014-05-08 2018-04-21
ES2774177T3 (es) 2014-09-15 2020-07-17 Plexxikon Inc Compuestos heterocíclicos y usos de estos
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CZ2015250A3 (cs) 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
HK1255102A1 (zh) 2015-09-21 2019-08-02 Plexxikon Inc. 杂环化合物及其应用
HUE050567T2 (hu) 2015-09-23 2020-12-28 Janssen Pharmaceutica Nv Triciklusos heterociklusok rák kezelésére
WO2017050865A1 (fr) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-hétéroaryle 1,4-benzodiazépines substituées et leurs utilisations pour le traitement du cancer
US9938273B2 (en) 2015-12-07 2018-04-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10160747B2 (en) 2016-03-16 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
RU2768479C2 (ru) * 2016-06-13 2022-03-24 Хемоцентрикс, Инк. Способы лечения рака поджелудочной железы
CN107722013B (zh) * 2016-08-11 2021-01-12 中国科学院上海药物研究所 去氮嘌呤类化合物及其药物组合物、制备方法和用途
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
IL294410B2 (en) 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018175311A1 (fr) 2017-03-20 2018-09-27 Plexxikon Inc. Formes cristallines de l'acide 4-(1-(1,1-di(pyridin-2-yl)éthyl)-6-(3,5-diméthylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoïque inhibiteur de bromodomaine
WO2018226846A1 (fr) 2017-06-07 2018-12-13 Plexxikon Inc. Composés et procédés de modulation de kinase
BR112019028235B1 (pt) 2017-07-25 2024-04-30 Plexxikon, Inc. Composições e seus métodos de preparação
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
CA3080197C (fr) 2017-10-27 2023-12-19 Plexxikon Inc. Formulation d'un compose modulant les kinases
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
AU2019216264B2 (en) 2018-01-31 2023-08-31 Heparegenix Gmbh Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11149011B2 (en) 2018-03-20 2021-10-19 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
WO2019243315A1 (fr) 2018-06-21 2019-12-26 Heparegenix Gmbh Inhibiteurs de protéine kinase tricycliques pour favoriser la régénération du foie ou réduire ou prévenir la mort des hépatocytes
SG11202012732UA (en) * 2018-07-16 2021-02-25 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2021007478A1 (fr) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Composés de sulfone et leurs compositions pharmaceutiques, et leurs applications thérapeutiques pour le traitement de maladies neurodégénératives
JP7629442B2 (ja) 2019-07-29 2025-02-13 ヘパリジェニックス ゲーエムベーハー 肝臓再生を促進または肝細胞死を縮減もしくは防止するためのヘテロアリール置換ピラゾロ－ピリジンタンパク質キナーゼ阻害剤
SI4073065T1 (sl) 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
CA3164361A1 (fr) 2020-01-15 2021-07-22 Heparegenix Gmbh Derives de 3-benzoyl-1h-pyrrolo[2,3-b]pyridine utilises en tant qu'inhibiteurs de mkk4 pour le traitement de maladies du foie
AU2021263383A1 (en) 2020-04-29 2022-11-24 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2021255212A1 (fr) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Agents de dégradation de braf
WO2025108405A1 (fr) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 Préparation d'un dérivé de quinazolinone destiné à être utilisé en tant qu'inhibiteur de kinase, et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
DE102005034406A1 (de) 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
GB0624084D0 (en) 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
JP2010533729A (ja) * 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応

Also Published As

Publication number Publication date
WO2010129567A1 (fr) 2010-11-11
AR076749A1 (es) 2011-07-06
US20100286142A1 (en) 2010-11-11
RU2011149485A (ru) 2013-06-20
AU2010246005A1 (en) 2011-12-01
CN102459262A (zh) 2012-05-16
CR20110562A (es) 2012-02-09
PE20120518A1 (es) 2012-05-24
JP2012526127A (ja) 2012-10-25
ECSP11011437A (es) 2011-12-30
EP2427433A1 (fr) 2012-03-14
EP2427462A1 (fr) 2012-03-14
US20120245174A1 (en) 2012-09-27
NI201100189A (es) 2012-01-11
BRPI1013843A2 (pt) 2016-04-12
ZA201108124B (en) 2014-04-30
TW201041888A (en) 2010-12-01
WO2010129570A1 (fr) 2010-11-11
US8198273B2 (en) 2012-06-12
NO20111508A1 (no) 2011-12-02
MX2011011737A (es) 2011-12-08
JP2012526128A (ja) 2012-10-25
CL2011002739A1 (es) 2012-04-09
US20120122860A1 (en) 2012-05-17
IL215908A0 (en) 2012-01-31
CA2759997A1 (fr) 2010-11-11
SG175810A1 (en) 2011-12-29
KR20140014386A (ko) 2014-02-06

Similar Documents

Publication Publication Date Title
MX2011011737A (es) Compuestos y metodos para la modulacion de las quinasas e indicaciones de los mismos.
MX2015013945A (es) Derivados de urea utiles como inhibidores de quinasa.
MX2017004128A (es) Derivados de diarilurea como inhibidores de quinasa p38.
ECSP109953A (es) Derivados de piridazinona
BRPI0815572A2 (pt) Compostos e composições como inibidores de quinases
EA201070667A1 (ru) 8-замещенные пиридо[2,3-в]пиразины и их применение
MX2015002044A (es) Pirazolil-ureas como inhibidores de quinasa.
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
UA97506C2 (xx) Інгібітори полі(adp-рибозо)полімерази$ингибиторы поли(adp-рибозо)полимеразы
EA201691294A2 (ru) ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
ME01291A (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
ATE534292T1 (de) Spiroverbindungen und anwendungsverfahren dafür
EA201100426A1 (ru) Бициклические ингибиторы киназы
UA111604C2 (uk) ЗАМІЩЕНІ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНОВІ СОЛІ
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA200970953A1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
MY156210A (en) Compounds and methods for kinase modulation, and indications therefor
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
WO2014033447A3 (fr) Inhibiteurs de kinase
PH12013501754A1 (en) Triazolopyridine compounds as pim kinase inhibitors
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
WO2008121687A3 (fr) Composés imidazo[1,2-a]pyridine en tant qu'inhibiteurs de la tyrosine kinase récepteur
EA200901603A1 (ru) Арил-эфирные производные пиридазинона
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami